ICD-10 · PDGM grouping
E31 Polyglandular dysfunction
All 8 codes in the E31 family, with the PDGM clinical group, comorbidity subgroup and primary-position rule CMS assigns, read from the CMS grouper crosswalk v07.2.26 and the CDC FY2027 code file.
Codes in family
8
Can lead a claim
8
Cannot lead a claim
0
What CMS assigns to E31
All 8 codes group to MMTA - Endocrine (5) and MMTA - Other (3). None of the 8 is assigned a comorbidity subgroup. Every code can lead a claim.
Every code in E31
Descriptions are CDC’s FY2027 wording; where CMS’s grouper abbreviates one, its form is shown beneath.
| Code | Description | Primary position | Clinical group | Comorbidity subgroup |
|---|---|---|---|---|
| E31.0 | Autoimmune polyglandular failure | Can lead a claim | I | None |
| E31.1 | Polyglandular hyperfunction | Can lead a claim | A | None |
| E31.2 Multiple endocrine neoplasia [MEN] syndromes | ||||
| E31.20 | Multiple endocrine neoplasia [MEN] syndrome, unspecified | Can lead a claim | I | None |
| E31.21 | Multiple endocrine neoplasia [MEN] type I | Can lead a claim | I | None |
| E31.22 | Multiple endocrine neoplasia [MEN] type IIA | Can lead a claim | I | None |
| E31.23 | Multiple endocrine neoplasia [MEN] type IIB | Can lead a claim | A | None |
| E31.8 | Other polyglandular dysfunction | Can lead a claim | A | None |
| E31.9 | Polyglandular dysfunction, unspecified | Can lead a claim | I | None |
Sources: CMS HH PPS Grouper Software v07.2.26, effective 2026-10-01, for the clinical group, comorbidity subgroup, code-first conventions and primary-position flags; CDC NCHS ICD-10-CM FY2027 code descriptions for the family title and code wording. This is the crosswalk Medicare runs a claim through. Grouping also depends on admission source, timing, the OASIS functional items and the rest of the diagnosis list.
The monthly home health regs digest
What CMS changed, what's due next, and what to do about it — one email a month, no fluff. Read the first issue